Compass Pathways plc, a biotechnology company focused on mental health innovations, announced the appointment of Justin Gover to its Board of Directors. Gover, who has over 25 years of biopharmaceutical industry experience and previously led GW Pharmaceuticals, joins as the company progresses towards potential approval and commercialization of their treatment for treatment-resistant depression. Dr. Linda McGoldrick will retire from the Board at the end of October after more than five years of service.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20250729752647) on July 29, 2025, and is solely responsible for the information contained therein.